KMT2A and leukemia: As such, we sought to assess how reducing MYB levels would impact on the maintenance of leukaemia types that are characterized by different levels of MYB expression, focusing on leukaemias driven either by MLL fusions, t(8;21) translocations or complex karyotypes.